Journal Article

Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma

Rausseo, Barbara Nassif, Talukder, Amjad, Elzohary, Lama, Katailiha, Arjun, Lizée, Gregory, Sun, Yimo, Wang, Yupeng, Du, Xueming, Li, Fenge, Wu, Huancheng, Wang, Zhiyu

2023

Overview

The epidermal growth factor receptor (EGFR) plays crucial roles in several important biological functions such as embryogenesis, epithelial tissue development, and cellular regeneration. However, in multiple solid tumor types overexpression and/or activating mutations of the EGFR gene frequently occur, thus hijacking the EGFR signaling pathway to promote tumorigenesis. Non-small cell lung cancer (NSCLC) tumors in particular often contain prevalent and shared EGFR mutations that provide an ideal source for public neoantigens (NeoAg). Studies in both humans and animal models have confirmed the immunogenicity of some of these NeoAg peptides, suggesting that they may constitute viable targets for cancer immunotherapies. Peptide vaccines targeting mutated EGFR have been tested in multiple clinical trials, demonstrating an excellent safety profile and encouraging clinical efficacy. For example, the CDX-110 (rindopepimut) NeoAg peptide vaccine derived from the EGFRvIII deletion mutant in combination with temozolomide and radiotherapy has shown efficacy in treating EGFRvIII-harboring glioblastoma multiforme (GBM) patients undergone surgery in multiple Phase I and II clinical trials. Furthermore, pilot clinical trials that have administered personalized NeoAg peptides for treating advanced-stage NSCLC patients have shown this approach to be a feasible and safe method to increase antitumor immune responses. Amongst the vaccine peptides administered, EGFR mutation-targeting NeoAgs induced the strongest T cell-mediated immune responses in patients and were also associated with objective clinical responses, implying a promising future for NeoAg peptide vaccines for treating NSCLC patients with selected EGFR mutations. The efficacy of NeoAg-targeting peptide vaccines may be further improved by combining with other modalities such as tyrosine kinase or immune checkpoint inhibitor (ICI) therapy, which are currently being tested in animal models and clinical trials. Herein, we review the most current basic and clinical research progress on EGFR-targeted peptide vaccination for the treatment of NSCLC and other solid tumor types.

• Publisher: MDPI AG,MDPI
• Subject: Animal models / Antitumor activity / Binding sites / Brain cancer / Cancer vaccines / Cell division / Cell growth / Clinical trials / Cohen, Stanley / Deletion mutant / Drug therapy / Effectiveness / Embryogenesis / Embryonic growth stage / Epidermal growth factor / epidermal growth factor receptor / Epidermal growth factor receptors / Gene amplification / Glioblastoma / Glioblastoma multiforme / Growth factors / Health aspects / Immune response (cell-mediated) / Immunogenicity / immunotherapy / Kinases / Ligands / Lung cancer / Lung cancer, Non-small cell / Lymphocytes / Lymphocytes T / Metastasis / Methods / Mutation / Non-small cell lung carcinoma / Patients / peptide vaccine / Peptides / Phosphorylation / Protein-tyrosine kinase / Proteins / Radiation therapy / Receptors / Review / Signal transduction / Small cell lung carcinoma / Solid tumors / Temozolomide / Tumorigenesis / Tumors / Tyrosine / Vaccination / Vaccines